Tagged with Opinion,

China Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry.   Napoleon once said: “China is a sleeping giant. Let her sleep, for when she wakes she will shake the world.” Well, in biotech, she is now wide awake I’ve recently returned from…

Medtech Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it?   The UK’s National Health Service has crippling sustainability challenges.   With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate…

M&A It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases in Q2 2018, with deal volumes in the quarter reminiscent of 2016 and 2017 levels [1]. I and others [234] continue…

Innovation “Imagine a world where every single ingredient inside every single pharmaceutical you take is traced from start to finish.” We can all agree that the healthcare system in the United States is in dire need of an overhaul. Technological advances propel us into the 21st Century, but the way data…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…